BC061237 Inhibitors
BC061237 is a protein intricately involved in cellular processes related to DNA repair and genomic stability. Functionally, BC061237 plays a pivotal role in maintaining the integrity of the genome by participating in various DNA repair mechanisms. Its involvement in crucial cellular processes underscores its significance in safeguarding the genome against potential damage, ensuring the fidelity of genetic information transfer during cell division. The general mechanisms of inhibition for BC061237 inhibitors revolve around intricate signaling pathways and cellular processes. Indirect inhibitors act by influencing these pathways, altering the cellular environment in ways that impact BC061237 function. For instance, inhibitors like ATRA and Rapamycin indirectly target BC061237 by modulating retinoic acid signaling and mTOR pathways, respectively. This indirect modulation reflects the interconnectedness of cellular signaling networks, demonstrating how alterations in one pathway can cascade to affect BC061237-associated processes.
Furthermore, inhibitors such as Wortmannin and Sorafenib disrupt BC061237 indirectly by targeting the PI3K/AKT and RAF/MEK/ERK pathways, respectively. This highlights the cross-talk between kinase pathways and BC061237-related signaling events. Additionally, agents like Niclosamide and Bortezomib indirectly influence BC061237 by disrupting Wnt/β-catenin and proteasome pathways, respectively, emphasizing the diverse cellular processes intersecting with BC061237 function. In summary, BC061237 inhibitors, whether direct or indirect, act on intricate cellular pathways, reflecting the complexity of cellular signaling networks. Understanding these pathways and their interconnected nature is crucial for comprehending the mechanisms through which BC061237 inhibitors exert their effects.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic Acid, all trans, a derivative of vitamin A, acts as an indirect inhibitor of BC061237. It modulates the retinoic acid signaling pathway, impacting cellular differentiation and proliferation. ATRA's influence on this pathway indirectly affects BC061237 by altering the cellular environment and gene expression patterns that intersect with BC061237-related pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences BC061237 by disrupting the mTOR signaling pathway. mTOR plays a role in cell growth and survival. The inhibition of mTOR by Rapamycin alters cellular processes, indirectly impacting BC061237 through cross-talk between mTOR and BC061237-associated pathways. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Fluorouracil, an antimetabolite, indirectly inhibits BC061237 by disrupting DNA synthesis. As BC061237 is involved in DNA repair mechanisms, the interference with DNA synthesis indirectly affects BC061237 by challenging its role in maintaining genomic integrity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB-431542 acts as an indirect inhibitor by targeting the TGF-β/Smad pathway. While avoiding direct modulation of TGF, it impacts downstream signaling events connected to BC061237. By influencing the TGF-β/Smad pathway, SB-431542 indirectly modulates BC061237 function, illustrating the interconnectedness of signaling cascades in cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly inhibits BC061237 by disrupting the PI3K/AKT pathway. BC061237 interacts with AKT, and Wortmannin's action on PI3K interferes with this interaction, indirectly influencing BC061237-associated cellular processes and downstream signaling events. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, indirectly affects BC061237 by targeting the RAF/MEK/ERK pathway. BC061237 interacts with components of this pathway, and Sorafenib's inhibition disrupts the signaling cascade, indirectly impacting BC061237-mediated cellular functions. The interconnected nature of kinase pathways highlights the indirect modulation of BC061237 by Sorafenib. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin, a DNA crosslinking agent, indirectly influences BC061237 by inducing DNA damage. BC061237 participates in DNA repair, and Cisplatin's impact on DNA structure indirectly challenges BC061237's role in maintaining genomic stability. The cellular response to Cisplatin-induced DNA damage indirectly intersects with BC061237-associated pathways, altering its cellular functions. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
Niclosamide, an anthelmintic drug, indirectly inhibits BC061237 by disrupting the Wnt/β-catenin pathway. Although avoiding direct modulation of Wnt, Niclosamide's action on the pathway influences downstream events that intersect with BC061237-related signaling, indirectly affecting BC061237-mediated cellular processes. The cross-talk between pathways highlights the indirect impact of Niclosamide on BC061237. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a Src/Abl kinase inhibitor, indirectly influences BC061237 by targeting Src kinase. BC061237 interacts with Src, and Dasatinib's inhibition disrupts this interaction, indirectly modulating BC061237-associated signaling events. The interconnected nature of kinase pathways illustrates Dasatinib's indirect impact on BC061237 by disrupting specific protein-protein interactions. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, a proteasome inhibitor, indirectly inhibits BC061237 by disrupting protein degradation pathways. BC061237 turnover is regulated by the proteasome, and Bortezomib's action on the proteasome indirectly impacts BC061237 levels, influencing its cellular functions. The connection between protein homeostasis and BC061237 illustrates the indirect modulation of BC061237 by Bortezomib. | ||||||